We are live on ! Find out more
CTKB icon

Cytek Biosciences

153 hedge funds and large institutions have $309M invested in Cytek Biosciences in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

14% more capital invested

Capital invested by funds: $270M → $309M (+$38.6M)

0.2% more ownership

Funds ownership: 62.68%62.88% (+0.2%)

3% less funds holding

Funds holding: 158153 (-5)

17% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 24

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
153
Holders Change
-5
Holders Change %
-3.16%
% of All Funds
2.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
20
Increased
62
Reduced
53
Closed
24
Calls
Puts
$2K
Net Calls
-$2K
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$57.4M -$1.83M -487,842 -3%
Focus Partners Wealth
2
Focus Partners Wealth
Massachusetts
$31.2M +$265K +70,576 New
TCM
3
Topline Capital Management
California
$24.1M +$6.43M +1,713,020 +33%
Vanguard Group
4
Vanguard Group
Pennsylvania
$24.1M -$3.12M -831,634 -11%
HA
5
HHLR Advisors
Cayman Islands
$23.1M
BCM
6
Brown Capital Management
Maryland
$17.2M -$8.08M -2,151,979 -30%
State Street
7
State Street
Massachusetts
$14.2M -$336K -89,395 -2%
Millennium Management
8
Millennium Management
New York
$11.9M +$9.36M +2,493,610 +270%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$11.2M -$890K -237,018 -7%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$9.66M +$202K +53,856 +2%
Wellington Management Group
11
Wellington Management Group
Massachusetts
$8.82M +$9.54M +2,541,046 New
RA
12
Royce & Associates
New York
$6.12M +$1.4M +373,456 +27%
Goldman Sachs
13
Goldman Sachs
New York
$6.03M +$2.71M +720,752 +71%
Morgan Stanley
14
Morgan Stanley
New York
$5.08M +$1.18M +313,020 +27%
Charles Schwab
15
Charles Schwab
California
$3.83M +$734K +195,431 +21%
AQR Capital Management
16
AQR Capital Management
Connecticut
$3.54M -$820K -218,503 -18%
Northern Trust
17
Northern Trust
Illinois
$3.52M -$309K -82,411 -8%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$2.86M -$240K -63,903 -7%
Renaissance Technologies
19
Renaissance Technologies
New York
$2.76M -$1M -267,595 -25%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$2.34M -$98.9K -26,344 -4%
Principal Financial Group
21
Principal Financial Group
Iowa
$2.16M +$191K +50,919 +9%
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$1.96M +$946K +251,929 +80%
UBS Group
23
UBS Group
Switzerland
$1.63M -$613K -163,363 -26%
Public Sector Pension Investment Board (PSP Investments)
24
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.48M +$289K +77,070 +22%
Invesco
25
Invesco
Georgia
$1.35M +$171K +45,467 +13%

CTKB Hedge Fund Activity: Q3 2025 in Review

153 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q3 2025, worth a combined $309M — up 14% from $270M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of CTKB and 20 opened new positions — a net loss of 4 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $9.54M. The largest seller was Brown Capital Management, cutting an estimated $8.08M.

  • 153 institutional investors held Cytek Biosciences (CTKB) as of Q3 2025, down from 158 in Q2 2025.
  • Funds reported $309M of Cytek Biosciences stock for Q3 2025, up 14% quarter-over-quarter.
  • 20 funds opened new Cytek Biosciences positions in Q3 2025 and 24 closed out, a net change of -4 holders.
  • The largest Cytek Biosciences buyer in Q3 2025 was Wellington Management Group, an estimated $9.54M added.
  • The largest Cytek Biosciences seller in Q3 2025 was Brown Capital Management, an estimated $8.08M sold.

Based on aggregated 13F filings for Q3 2025.